Table 1.

Change from baseline in FEV₁ AUC_(0–12) on day 1 and trough FEV₁ on day 29

	Wixela Inhub	Advair Diskus	Placebo
Day 1 change from baseline in FEV1 AUC(0–12)
n	497	494	94
LS mean (95% CI)	3.973 (3.639–4.308)	3.541 (3.228–3.854)	0.840 (0.248–1.432)
Difference from placeboa
LS mean (95% CI)	3.133 (2.472–3.795)c	2.701 (2.047–3.3556)c
Equivalence test
LS mean ratio (90% CI)	1.120 (1.016–1.237)
Day 29 change from baseline in trough FEV1
n	498	497	99
LS mean (95% CI)	0.291 (0.259–0.323)	0.273 (0.241–0.305)	0.057 (–0.012–0.127)
Difference from placeboc
LS mean (95% CI)	0.234 (0.159–0.309)b	0.215 (0.140–0.291)b
Equivalence test
LS mean (90% CI)	1.069 (0.938–1.220)

ANCOVA analysis of covariance, AUC_(0–12) area under the effect curve over 12 h post-dose, CI confidence interval, FEV₁ forced expiratory volume in 1 s, LS least squares

^aBased on ANCOVA

^bP < 0.0001

^cDifference of LS means (Inhub minus placebo; Diskus minus placebo) from the ANCOVA model